Quince Therapeutics (QNCX) Fundamental Analysis: Revenue, Earnings & Valuation

5.08 / 10

Netural

The fundamentals score 5.1/10, showing modest quality. Cash‑to‑market and inventory turnover are strong, and Asset‑MV carries the highest weight, indicating solid asset base. However, revenue‑to‑market and gross profit margin are weak, limiting earnings growth potential.

Analysis Checks(7/10)

Revenue-MV

Value-0.28

Score1/3

Weight11.48%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value78.03

Score3/3

Weight2.97%

1M Return1.54%

Inventory turnover ratio

Value47.95

Score3/3

Weight15.23%

1M Return6.74%

Gross profit margin (%)

Value36.92

Score1/3

Weight-1.08%

1M Return-0.63%

PB-ROE

Value-0.48

Score1/3

Weight12.76%

1M Return5.29%

Income tax / Total profit (%)

Value-0.15

Score2/3

Weight2.04%

1M Return1.04%

Fixed assets turnover ratio

Value7895.57

Score3/3

Weight1.96%

1M Return1.06%

Cost of sales ratio (%)

Value70.31

Score3/3

Weight8.81%

1M Return4.32%

Asset-MV

Value-0.49

Score3/3

Weight32.32%

1M Return11.84%

Cash-MV

Value-0.09

Score2/3

Weight13.53%

1M Return5.94%

Is QNCX fundamentally strong?

QNCX scores 5.08/10 on fundamentals and holds a Fair valuation at present. Backed by its -285.35% ROE, 0.00% net margin, -0.11 P/E ratio, 5.23 P/B ratio, and 3.23% earnings growth, these metrics solidify its Netural investment rating.